Please login to the form below
Combination treatment
This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
BMS gains FDA approval for second Opdivo combo in kidney cancer
BMS’ PD-L1 inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients. ... The European Medicines Agency (EMA) has already validated the completion of
Latest news
-
BMS aims for US approval of Opdivo combo in stomach cancer
The US Food and Drug Administration (FDA) has accepted a priority review for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) plus chemotherapy combination in stomach cancer. ... Although Opdivo lags behind Keytruda, BMS has been aiming for a number of
-
Sanofi gains access to antibody tech with Kymab acquisition
Aside from KY1005, Kymab’s pipeline also includes an early-stage oncology candidate – KY1044 – which is currently being investigated as a monotherapy treatment and in combination with a PD-L1 inhibitor. ... The Kymab acquisition adds KY1005 to our
-
Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation
The BTD covers the combination treatment in the first-line setting for people with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR ... Results from this study showed that, after an average follow-up of
-
Roche gets EU approval for fixed-dose Herceptin/Perjeta combination
The new combination treatment, containing Herceptin (trastuzumab) and Perjeta (pertuzumab) with hyaluronidase, has been authorised for use for the treatment of early and metastatic HER2-positive breast cancer. ... This means that the combination
-
Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval
Drug approved for emergency use in combination with Gilead's remdesivir. Eli Lilly and Incyte’s arthritis treatment baricitinib has been repurposed as a COVID-19 treatment, scoring an emergency use ... The EUA covers baricitinib in combination with
More from news
Approximately 0 fully matching, plus 287 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
-
Deal Watch April 2016
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
-
Pharma deals in April 2015
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
-
Pharma deals during July 2014
Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business
-
Interview: AstraZeneca's Susan Galbraith
And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Oncosec
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
-
Marketing strategy in complex environments
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Sinovac’s COVID-19 vaccine appears safe in older adults
- New study identifies drugs that are safe to use in COVID-19 treatment
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- Merck ends its COVID-19 vaccine programme after disappointing early trial results
- AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU
- Pfizer/BioNTech reach vaccine supply agreement with COVAX
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- An EU emergency health fund to limit the impact of future crises
- Mistrust in medical research: a patient perspective
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- An EU emergency health fund to limit the impact of future crises
- Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
Quick links
Infographics
